Center for Surveillance, Epidemiology, and Laboratory Services

Risk Assessment: The Foundation of Every Good Biorisk Management System

Reynolds M Salerno, PhD

Director Division of Laboratory Systems March 2, 2020



U.S. Department of Health and Human Services Centers for Disease Control and Prevention

Risk Management Well Accepted





Biological Community Has Embraced Risk Management

		WORKSHOP	September 2011
Standay	ds All about ISO Taking part Store Q)	AGREEMENT	
ISO		ICS 07.100.01	Supersedes CWA 1
			English version
ICS > 03 > 03.100 > 03.100.70		Laborate	ory biorisk management
ISO 35001:2019		This CEN Workshop Agreement has been drafted and a which is indicated in the foreword of this Workshop Agree The formal process followed by the Workshop in the dee Membras of CEN has realistic this Midnand Manchen of C	approved by a Workshop of representatives of interested parties, the co eement. velogment of this Workshop Agreement has been endorsed by the Nati PSN nor the CPU Menonexpect Querte one he had accountable for the
		The result of this CEN Workshop Agreement or possible or content of this CEN Workshop Agreement or possible or This CEN Workshop Agreement can in no way be held a	as being an official standard developed by CEN and its Members.
Useriely menomenant text leberateries and athen us		The out the anapping coment out in the way be need a	as being an official standard developed by derivations included.
biorisk management for laboratories and other re	lated organisations	This CEN Workshop Agreement is publicly available as	a reference document from the CEN Members National Standard Bodi
biorisk management for laboratories and other re	lated organisations	This CEN Workshop Agreement is publicly available as: CEN members are the national standards bodies of Aus Finland, France, Germany, Greece, Hungary, Ledand, In Portugal, Romaria, Sovokia, Sovokia, Sania, Sweden,	a reference document from the CEN Members National Standard Bodi stria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Er reland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norwa Switzerland and United Kingdom.
DIOTISK management for laboratories and other re	BUY THIS STANDARD	This CEN Workshop Agreement is publicly available as: CEN members are the national standards bodies of Aus Finland, France, Germany, Green, Hungar, Iodand, Portugal, Romania, Siovakia, Stovenia, Span, Sweden,	a reference document from the CEN Members National Standard Bodi strig, Betguin, Butgaris, Croatis, Cyprus, Czech Resublic, Denmark, Er elend, Taby, Labu, Lihunain, Lurembourg, Maita, Netherlands, Norwa Switzerland and United Kingdom.
DIOTISK management for laboratories and other re	BUY THIS STANDARD	This CEN Workshop Agreement is publicly available as: CEN members are the national standards bodies of Aus Finlanc, France, Genary, Green, Hungray, Iodand, Postugal, Romana, Slovaku, Slovena, Spain, Sleeden,	a reference document from the CEN Members National Standard Bodi tatis, Bergium, Bulgaria, Costia, Coypus, Casch Republic, Denmak, E e referend, Taby Lidek / Tikonani, Lucembourg, Mata, Netherlands, Norwe Switzenand and United Krigdom.
	BUY THIS STANDARD FORMAT	This CEN Workshop Agreement is publicly available as. CEN members are the national standards bodies of Aus Finland, France, Germany, Greese, Hungar, Iostani, Portugal, Romania, Stovakia, Stovenia, Spain, Sweden,	a reference document from the CEN Members National Standard Book trits, Belgium, Bulgana, Costa, Cyprus, Czech Republic, Denmark, Es event, Taily, Lativ, Uthinani, Luxemburg, Matta, Netherlands, Norway Switzerland and United Kingdom.
ABSTRACT PREVIEW This document defines a process to identify, assess, control, and monitor the risks associated with hazardous biological materials. This document is applicable to any laboratory or other organization that works with, stores, transports, and/or disposes of hazardous biological materials. This document existing	BUY THIS STANDARD FORMAT PAPER	This CEN Workshop Agreement is publicly available as: CEN members are the national standards bodies of Aus Finlanc, France, Germany, Geree, Hungray, Iostan, D Poingal, Romana, Blovaku, Blovena, Spain, Sweden,	a reference document from the CEN Members National Standard Bod datis, Bergium, Bulgaria, Costia, Corpus, Czech Republic, Denmark, E. Homan, Law Carlon, Carlon, Carlon, Carlon, Carlon, Matta, Netherlands, Noive Switzenand and United Knigdom.
ABSTRACT PREVIEW This document defines a process to identify, assess, control, and monitor the risks associated with hazardous biological materials. This document is applicable to any laboratory or other organization that works with, stores, transports, and/or disposes of hazardous biological materials. This document is intended to complement existing International Standards for laboratories.	BUY THIS STANDARD FORMAT PAPER	This CEN Workshop Agreement is publicly available as: CEN members are the national standards bodies of Aus Finiance, France, Genarry, Clerce, Hurgary, Cleated, Postugal, Romana, Bovatiu, Stovena, Spain, Sweden,	a reference document from the CEN Members National Standard Bod tatis, Bergium, Bulgaria, Consta, Cyprus, Czech Republic, Denmak, E. Bergin, Bay, Lako, Humania, Luenenourg, Matta, Netherlands, Norwe Switzenend and United Krigdom.
ABSTRACT PREVIEW This document defines a process to identify, assess, control, and monitor the risks associated with hazardous biological materials. This document is applicable to any laboratory or other organization that works with, stores, transports, and/or disposes of hazardous biological materials. This document is intended to complement existing international Standards for laboratories. This document is not intended for laboratories that test for the presence of microorganisms and/or toxins in food or feedstuffs. This document is not intended for the management of risks from the use of genetically modified crops in review the presence of microorganisms.	BUY THIS STANDARD FORMAT PAPER CHF 1:	This CEN Workshop Agreement is publicly available as: CEN members are the national standards bodies of Aus Finlanc, France, Germany, Green, Hungrup, Iostan, Poingal, Romana, Blovaku, Blovena, Spain, Bieden,	a reference document from the CEN Members National Standard Bod tatis, Bergium, Bulgaria, Costat, Cypras, Czech Republic, Demmark, E Method, Baly, Lado, Humanik, Lamenbourg, Matta, Netherlands, Norw Statzanson and United Krigdom.
DIOTISK INALIAGEMENT TOT LADOFACOTIES AND OTHER FE ABSTRACT PREVIEW This document defines a process to identify, assess, control, and monitor the risks associated with hazardous biological materials. This document is applicable to any laboratory or other organization that works with, stores, transports, and/or disposes of hazardous biological materials. This document is intended to complement existing international Standards for laboratories. This document is not intended for laboratories that test for the presence of microorganisms and/or toxins in food or feedstuffs. This document is not intended for the management of risks from the use of genetically modified crops in agriculture.	BUY THIS STANDARD FORMAT PAPER CHF 1:	The CEN Workshop Agreement is publicly available as. CEN members are the national standards bodies of Aus Finitanc, Finitanc, Grane, General, Clever, Augury, Iotand, Postugal, Romana, Blovatiu, Stovena, Span, Sweden, Standard, Stovena, Span, Sweden, Standard, Standard, Standa	a reference document from the CEN Members National Standard Boa tatis, Berjoin, Bulgaria, Consta, Cypran, Czech Republic, Denmak, F energia, Hay Lakot, Humania, Luenenbourg, Matta, Netherlands, Norw Switzenend and United Forgatom.

© 2011 CEN All rights of exploitation in any form and by any means reserved worldwide for CEN national Member

Ref. No.:CWA 15793:2011 D/E/F

Laboratory Biorisk Management

- Risk Management
 - Assessment
 - Mitigation
 - Performance/Evaluation
- Dynamic and iterative process
- Various models



LET'S PRACTICE

Division of Laboratory Systems

New (fictitious) Influenza Outbreak!



This and the subsequent slides are fictitious for this risk assessment presentation purpose only.

Risk Assessment Scenario

We are a **medical director** in charge of a **core microbiology laboratory** at a large academic teaching hospital.

Our laboratory is in the middle of a region of the country hard hit by **novel influenza virus H20N20**.

Our laboratory serves as the referral laboratory for two adjacent states, as well as its own.

Division of Laboratory Systems

Risk Assessment Scenario

Influenza-H20N20 has a high mortality rate (**2.5%**) and morbidity rate (**50%**); No treatment US Food and Drug Administration has issued an **Emergency Use Authorization** (EUA) for a new diagnostic test US Centers for Disease Control and Prevention has sent this **real-time RT PCR** (rRT-PCR) kit to our laboratory to verify and begin patient testing

Risk Assessment Scenario

The majority of staff is moderately competent (good not great); staff competency is assessed annually.

Few molecular technologists use the laboratory's biosafety cabinet frequently.

The facility usually double-bags its waste.

There are no additional laboratory staff to assist during high test volume periods.

Facility Design



Specimen Workflow



Examples of What Can Go Wrong During this Workflow

Sample Receipt (1)

- Suspected vs. confirmatory (sample mix up)
- Broken samples
- Improper packaging
- May not be decontaminated
- Misuse of personal protective equipment (PPE)
- Leaky package which leads to exposure

Extraction (2)

- Sample Contamination
- Master-mix reagent spill*
- Misuse of PPE
- Improper use of the biosafety cabinet (BSC)
- Improper inactivation during extraction

*Example of a chemical risk

Master Mix Room (3)

- Reagent contamination
- Master-mix reagent spill*
- Improper use of PPE

Amplification Room (4)

- Improper use of PPE
- Sample contamination
- Power failure

Post-Amplification/Waste (5)

- No/limited PPE
- Mishandling of waste
- Inappropriate waste disposal

Risks Selected for this Assessment

Improper use of the

Sample mix-up during specimen	during the extraction phase	
unpackaging Improper handling of	Improper inactivation during the extraction phase	
waste from initial		
sample processing	Misuse of personal protective equipment during	

protective equipment during the amplification stage

Misuse of personal

Improper handling of waste after the amplification stage

the extraction phase

How to Assess these Risks?

Risk Matrix

	SEVERITY				
Probability	Negligible	Minor	Serious	Critical	Catastrophic
Frequent	Low	Moderate	High	High	High
Probable	Low	Moderate	High	High	High
Occasional	Low	Moderate	Moderate	High	High
Remote	Low	Low	Moderate	Moderate	High
Improbable	Low	Low	Low	Moderate	Moderate

LET'S ASSESS OUR RISKS

Division of Laboratory Systems

Weighted Criteria to Assess the Risks



Likelihood Scoring Table: Sample Mix-up During Specimen Unpackaging

Likelihood Criteria and Weights	Raw Score	Weighted Score
Hazard characteristics (20%)		
1. The hazard is extremely fragile and has poor transmissibility		0
2.5. The hazard is moderately stable and/or moderate transmissibility		0
4. The hazard is very stable with strong transmissibility, or its stability/transmissibility is unknown	4	0.8
Staff training and competency (20%)		
1. All highly trained and competent staff for the specific activity		0
2. Most staff highly trained/competent staff but few moderately trained/competent	2	0.4
3. Few highly trained/competent staff and many moderately trained/competent		0
4. Most/all staff poorly trained and/or incompetent for the specific activity		0
Engineering controls (15%)		
1. All needed engineering controls in place and properly certified/maintained	1	0.15
2. Most but not all needed engineering controls in place and properly certified/maintained		0
3. Few/most of needed engineering controls in place and some of those not properly		
certified/maintained		0
4. Few/none of needed engineering controls in place and some/all of those not properly		
certified/maintained		0

Likelihood Scoring Table: Sample Mix-up During Specimen Unpackaging

Likelihood Criteria and Weights	Raw Score	Weighted Score
Administrative controls (15%)		
1. All necessary administrative controls in place and appropriately maintained by management	1	0.15
2. Most but not all necessary administrative controls in place and appropriate maintained by management		0
3. Few/most of necessary administrative controls in place and some of those not properly maintained		0
4. Few/none of necessary administrative controls in pace and some/all of those not properly maintained		0
Procedural controls (SOPs, protocols) (15%)		
1. All necessary procedural controls in place and appropriately maintained		0
2. Most but not all necessary procedural controls in place and appropriate maintained	2	0.3
3. Few/most of necessary procedural controls in place and some of those not properly maintained		0
4. Few/none of necessary procedural controls in place and some/all of those not properly maintained		0
Personal protective equipment (15%)		
1. All necessary PPE in use and appropriately maintained	1	0.15
2. Most but not all necessary PPE in use and appropriate maintained		0
Few/most of necessary PPE in use and some of those not properly maintained		0
4. Few/none of necessary PPE in use and some/all of those not properly maintained		0
TOTAL LIKELIHOOD SCORE		1.95

Consequences Scoring Table: Sample Mix-up During Specimen Unpackaging

Consequences Criteria and Weights	Raw Score	Weighted Score
Hazard characteristics (80%)		
1. Exposure to the hazard would not cause any morbidity or mortality		0
2. Exposure to the hazard could only cause morbidity and only to immuno compromised or elderly		0
3. Exposure to the hazard could could cause serious morbidity but limited mortality	3	2.4
4. Exposure to the hazard would result in high rates of morbidity and mortality		0
Vaccines and therapies (20%)		
1. There are highly effective vaccines and therapies available and all staff are vaccinated against this		
particular disease or the disease causes no morbidity and mortality		0
2. There are highly effective vaccines and/or therapies available but only some staff are vaccinated	0	0
3. There are vaccines and/or therapies available but their efficacy is limited		0
4. There are no vaccines or therapies available for the disease that this hazard would cause	4	0.8
TOTAL CONSEQUENCES SCORE		3.2

Risk: Sample Mix-up During Specimen Unpackaging





Division of Laboratory Systems

Excellent Laboratories, Outstanding Health 20

Assessment of the Selected Risks



- A: Sample mix-up during specimen unpackaging
- ▲ B: Improper handling of waste from initial sample processing
- ◆ C: Improper use of the BSC
- D: Improper inactivation during extraction phase
- ★ E: Misuse of PPE during the extraction phase
- F: Misuse of PPE during the amplification stage
- G: Improper handling of waste after amplification stage

Risk Mitigation – Improper Use of the BSC

Likelihood Criteria	Before	After
Hazard characteristics	4	4
Staff training and competency	3	
Engineering controls	3	$\overline{(2)}$
Administrative controls	7	
Procedural controls (SOPs,	Z	
protocols)	3	
Personal protective equipment	3	3
Total Weighted Likelihood Score	2.9	2.2

Risk Mitigation – Misuse of PPE during the Extraction Phase

Likelihood Criteria	Before	After
Hazard characteristics	4	4
Staff training and competency	3	
Engineering controls	2	2
Administrative controls	2	2
Procedural controls (SOPs,	J	
protocols)	3	(2)
Personal protective equipment	3	
Total Weighted Likelihood Score	3.05	2.2

Accepted Risks



- A: sample mixup during specimen unpackaging
- ▲ B: improper handling of waste from initial sample processing
- ◆ C: improper use of the BSC
- D: improper inactivation during extraction phase
- × E: misuse of PPE during the extraction phase
- F: misuse of PPE during the amplification stage
- G: improper handling of waste after amplification stage

Performance/Evaluation

How will we monitor the effectiveness of our chosen mitigation measures?

Exercise **Protocols**

Assess Training

> Document and disseminate the results of this evaluation!

Create a Culture of Risk Management



New Risk Assessment Course by CDC



Coming Soon! Laboratory Risk Management

www.cdc.gov/labtraining



For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov

Images used in accordance with fair use terms under the federal copyright law, not for distribution.

Use of trade names is for identification only and does not imply endorsement by U.S. Centers for Disease Control and Prevention.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of Centers for Disease Control and Prevention.